Doxorubicin and cyclophosphamide induce cognitive dysfunction and activate the ERK and AKT signaling pathways

• Published in: Behavioural brain research Vol. 292; pp. 133 - 141
• Main Authors: Salas-Ramirez, Kaliris Y, Bagnall, Ciara, Frias, Leslie, Abdali, Syed A, Ahles, Tim A., Hubbard, Karen
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.10.2015
• Subjects: Age Factors; Aging; AKT signaling; Animals; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Behavior; Behavior, Animal - drug effects; Brain-Derived Neurotrophic Factor - drug effects; Cognition - drug effects; Cognition Disorders - chemically induced; Cognition Disorders - enzymology; Cognitive dysfunction; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Disks Large Homolog 4 Protein; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; ERK signaling; Female; Hippocampus - drug effects; Hippocampus - metabolism; Intracellular Signaling Peptides and Proteins - metabolism; MAP Kinase Signaling System - drug effects; Membrane Proteins - metabolism; Neuronal Plasticity - drug effects; Neuronal Plasticity - physiology; Proto-Oncogene Proteins c-akt - metabolism; Rat; Rats; Rats, Inbred SHR; Signal Transduction - drug effects; Spatial Memory - drug effects; ERK signaling; Aging; Behavior; Rat; AKT signaling; Cognitive dysfunction

•Chemotherapy impairs working and spatial memory but not anxiety.•Chemotherapy transiently impairs locomotor activity.•Chemotherapy induces the Akt and ERK 1/2 signaling pathways. Chemotherapy is associated with long-term cognitive deficits in breast cancer survivors. Studies suggest that these impa...